These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

529 related articles for article (PubMed ID: 26993824)

  • 21. Non-alcoholic fatty liver disease after liver transplantation in patients with non-alcoholic steatohepatitis and cryptogenic cirrhosis: the impact of pre-transplant graft steatosis.
    Eshraghian A; Nikeghbalian S; Kazemi K; Shamsaeefar A; Geramizadeh B; Malek-Hosseini SA
    HPB (Oxford); 2020 Apr; 22(4):521-528. PubMed ID: 31431413
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Liver transplantation for hepatitis B virus: Decreasing indication and changing trends.
    Al-Hamoudi W; Elsiesy H; Bendahmash A; Al-Masri N; Ali S; Allam N; Al Sofayan M; Al Bahili H; Al Sebayel M; Broering D; Saab S; Abaalkhail F
    World J Gastroenterol; 2015 Jul; 21(26):8140-7. PubMed ID: 26185387
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Histologically proven non-alcoholic fatty liver disease and clinically related factors in recipients after liver transplantation.
    Kim H; Lee K; Lee KW; Yi NJ; Lee HW; Hong G; Choi Y; You T; Suh SW; Jang JJ; Suh KS
    Clin Transplant; 2014 May; 28(5):521-9. PubMed ID: 24579874
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lower rates of receiving model for end-stage liver disease exception and longer time to transplant among nonalcoholic steatohepatitis hepatocellular carcinoma.
    Young K; Aguilar M; Gish R; Younossi Z; Saab S; Bhuket T; Liu B; Ahmed A; Wong RJ
    Liver Transpl; 2016 Oct; 22(10):1356-66. PubMed ID: 27348270
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Hepatic parenchimatous damage and perfusion disturbance in the progression of nonalcoholic fatty liver disease].
    Dudanova OP; Belavina IA
    Eksp Klin Gastroenterol; 2014; (8):41-5. PubMed ID: 25911911
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of body mass index in liver transplantation for nonalcoholic fatty liver disease and alcoholic liver disease.
    O'Neill S; Napetti S; Cornateanu S; Sutherland AI; Wigmore S; Oniscu GC; Adair A
    HPB (Oxford); 2017 Dec; 19(12):1074-1081. PubMed ID: 28888774
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevalence and indicators of portal hypertension in patients with nonalcoholic fatty liver disease.
    Mendes FD; Suzuki A; Sanderson SO; Lindor KD; Angulo P
    Clin Gastroenterol Hepatol; 2012 Sep; 10(9):1028-33.e2. PubMed ID: 22610002
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nonalcoholic Fatty Liver Disease: Key Considerations Before and After Liver Transplantation.
    Patel YA; Berg CL; Moylan CA
    Dig Dis Sci; 2016 May; 61(5):1406-16. PubMed ID: 26815171
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.
    Traussnigg S; Kienbacher C; Halilbasic E; Rechling C; Kazemi-Shirazi L; Hofer H; Munda P; Trauner M
    Dig Dis; 2015; 33(4):598-607. PubMed ID: 26159280
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical and Genetic Risk Factors of Recurrent Nonalcoholic Fatty Liver Disease After Liver Transplantation.
    Satapathy SK; Tran QT; Kovalic AJ; Bontha SV; Jiang Y; Kedia S; Karri S; Mupparaju V; Podila PSB; Verma R; Maluf D; Mas V; Nair S; Eason JD; Bridges D; Kleiner DE
    Clin Transl Gastroenterol; 2021 Feb; 12(2):e00302. PubMed ID: 33555168
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nonalcoholic steatohepatitis: the new frontier for liver transplantation.
    Bzowej NH
    Curr Opin Organ Transplant; 2018 Apr; 23(2):169-174. PubMed ID: 29356708
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nonalcoholic fatty liver disease and liver transplantation - Where do we stand?
    Mikolasevic I; Filipec-Kanizaj T; Mijic M; Jakopcic I; Milic S; Hrstic I; Sobocan N; Stimac D; Burra P
    World J Gastroenterol; 2018 Apr; 24(14):1491-1506. PubMed ID: 29662288
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Liver transplantation and non-alcoholic fatty liver disease.
    Zezos P; Renner EL
    World J Gastroenterol; 2014 Nov; 20(42):15532-8. PubMed ID: 25400437
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of nonalcoholic fatty liver disease and liver cancer.
    Schulz PO; Ferreira FG; Nascimento Mde F; Vieira A; Ribeiro MA; David AI; Szutan LA
    World J Gastroenterol; 2015 Jan; 21(3):913-8. PubMed ID: 25624725
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Poor Survival After Retransplantation in NASH Cirrhosis.
    Thuluvath AJ; Chen PH; Thuluvath PJ; Kantsevoy S; Savva Y
    Transplantation; 2019 Jan; 103(1):101-108. PubMed ID: 29470354
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-Term Follow-Up Study of Liver-Related Outcome After Bilio-Pancreatic Diversion in Patients with Initial, Significant Liver Damage.
    Giannini EG; Coppo C; Romana C; Camerini GB; De Cian F; Scopinaro N; Papadia FS
    Dig Dis Sci; 2018 Jul; 63(7):1946-1951. PubMed ID: 29629490
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reconsideration of liver transplantation for portal hypertension due to hepatitis B cirrhosis: a single center experience.
    Wang M; Li C; Yan LN; Wen TF; Li B; Zhang Y; Jiang L; Liang GL
    Hepatogastroenterology; 2013 May; 60(123):496-500. PubMed ID: 23635447
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Portal vein thrombosis and renal dysfunction: a national comparative study of liver transplant recipients for NAFLD versus alcoholic cirrhosis.
    Molinari M; Fernandez-Carrillo C; Dai D; Dana J; Clemente-Sanchez A; Dharmayan S; Kaltenmeier C; Liu H; Behari J; Rachakonda V; Ganesh S; Hughes C; Tevar A; Al Harakeh H; Emmanuel B; Humar A; Bataller R
    Transpl Int; 2021 Jun; 34(6):1105-1122. PubMed ID: 33780554
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Liver transplantation for non-alcoholic fatty liver disease.
    Germani G; Becchetti C
    Minerva Gastroenterol Dietol; 2018 Jun; 64(2):138-146. PubMed ID: 29249127
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cystic fibrosis and portal hypertension: Distal splenorenal shunt can prevent the need for future liver transplant.
    Lemoine C; Lokar J; McColley SA; Alonso EM; Superina R
    J Pediatr Surg; 2019 May; 54(5):1076-1082. PubMed ID: 30792095
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.